181 related articles for article (PubMed ID: 12702528)
1. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.
Hosing C; Saliba RM; McLaughlin P; Andersson B; Rodriguez MA; Fayad L; Cabanillas F; Champlin RE; Khouri IF
Ann Oncol; 2003 May; 14(5):737-44. PubMed ID: 12702528
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience.
Verdonck LF
Leuk Lymphoma; 1999 Jun; 34(1-2):129-36. PubMed ID: 10350340
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
Verdonck LF; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK
Blood; 1997 Nov; 90(10):4201-5. PubMed ID: 9354692
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases.
Picleanu AM; Novelli S; Monter A; Garcia-Cadenas I; Caballero AC; Martino R; Esquirol A; Briones J; Sierra J
Ann Hematol; 2017 May; 96(5):787-796. PubMed ID: 28168350
[TBL] [Abstract][Full Text] [Related]
8. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
9. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P; Kim HT; Ho VT; Cutler CS; Koreth J; Antin JH; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2008 Apr; 14(4):418-25. PubMed ID: 18342784
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma.
Mitterbauer M; Neumeister P; Kalhs P; Brugger S; Fischer G; Dieckmann K; Hoecker P; Hinterberger W; Linkesch W; Simonitsch I; Jaeger U; Lechner K; Mannhalter C; Mitterbauer G; Greinix HT
Leukemia; 2001 Apr; 15(4):635-41. PubMed ID: 11368367
[TBL] [Abstract][Full Text] [Related]
12. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
13. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
Rezvani AR; Storer B; Maris M; Sorror ML; Agura E; Maziarz RT; Wade JC; Chauncey T; Forman SJ; Lange T; Shizuru J; Langston A; Pulsipher MA; Sandmaier BM; Storb R; Maloney DG
J Clin Oncol; 2008 Jan; 26(2):211-7. PubMed ID: 18056679
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Bertz H; Illerhaus G; Veelken H; Finke J
Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.
Kim JW; Kim BS; Bang SM; Kim I; Kim DH; Kim WS; Yang DH; Lee JJ; Lee JH; Kim JS; Sohn SK; Yhim HY; Kwak JY; Yoon SS; Lee JS; Park S; Kim BK;
Ann Hematol; 2011 Dec; 90(12):1409-18. PubMed ID: 21468694
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Koenigsmann M; Casper J; Kahl C; Basara N; Sayer HG; Behre G; Theurich S; Christopeit M; Mohren M; Reichle A; Metzner B; Ganser A; Stadler M; Uharek L; Balleisen L; Hinke A; Hinke R; Niederwieser D
Bone Marrow Transplant; 2014 Mar; 49(3):410-5. PubMed ID: 24362366
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
